GlassScriptPhysician profile
Michael M Raffinan
NPI 1346202322
$7,095.67
in general payments reported to CMS, 2019-2025
37 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $49.54 · 2021: $600 · 2022: $925 · 2023: $1,239 · 2024: $1,697 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,375.74 | 2021-2025 | |
| Viiv Healthcare Company | $813.92 | 2022-2025 | Apretude |
| Lilly USA, LLC | $762.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $758.91 | 2019-2025 | Breztri, Airsupra, Lokelma |
| Gilead Sciences, INC. | $563.56 | 2019-2025 | |
| Bausch Health US, LLC | $297.62 | 2021-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $248.26 | 2022-2025 | Azstarys |
| Pfizer INC. | $236.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.65 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $198.89 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $163.25 | 2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $147.93 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $133.10 | 2021-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $115.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $109.29 | 2019-2025 | Krystexxa, Tavneos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $107.56 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Mallinckrodt Hospital Products INC. | $82.22 | 2022-2023 | Acthar |
| Astellas Pharma US INC | $78.25 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $74.45 | 2019-2023 | Jynarque |
| Idorsia Pharmaceuticals US INC | $72.76 | 2022-2023 | Quviviq |
| Abbott Laboratories | $63.43 | 2022-2023 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $59.32 | 2022-2023 | Aptima |
| Phadia US INC. | $54.06 | 2019-2025 | Immunocap |
| Kaleo, INC. | $49.82 | 2022 | |
| Dexcom, INC. | $46.84 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $38.63 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.58 | 2025 | Zoryve |
| Itamar Medical INC | $26.70 | 2025 | Watchpatone |
| Phathom Pharmaceuticals, INC. | $26.24 | 2025 | Voquezna |
| Amag Pharmaceuticals, INC. | $25.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.42 | 2023 | Evkeeza |
| Horizon Therapeutics Plc | $20.87 | 2022 | |
| Genentech USA, INC. | $20.06 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.00 | 2019 | |
| Antares Pharma, INC. | $18.69 | 2023 | Xyosted, Tlando, Nocdurna |
| Arbor Pharmaceuticals, INC. | $14.68 | 2019 | |
| Optinose US, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raffinan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.